Iron Deficiency in children is common problem. Its mechanism could be nutritional or due to lack of iron absorption. Several conditions are associated with IDA. Presence of inflammation further complicate attempts to make a definitive diagnoses or accurately quantify reponse to therapy.
Commentary (Editorials)
The remarks on our articles are very well appreciated. The author of the letter mentions several points that are very appropriate. To begin with is the diagnoses of iron-deficiency anemia (IDA) in the pediatric population, particularly in the setting of inflammation. There is not a single practical parameter that could be used as a routine daily test. Serum iron is a labile value, and inflammation is associated with high ferritin and low serum total iron binding capacity (TIBC) that makes it hard to interpret iron saturation. If we solve that issue, we are left with the variable definition of anemia by age if not by gender, altitude, and geographic location. The therapeutic effect of iron therapy will depend on several factors. Inflammation can affect both iron absorption and utilization. Intravenous (IV) iron therapy bypasses the first but not necessarily the latter. Also, underlying comorbidities hypothetically may affect the response. Finally, what level of hemoglobin justifies the potential risk of an iron infusion? Our practice-defined indications were by a rapidly declining hemoglobin even if it was above 10 g/ dL or a declining hemoglobin in the face of inability to administer/failure of oral supplementation or oral iron challenge. On rare occasions, a postoperative patient with a critical hemoglobin level (<8 g/dL) was infused with IV iron regardless of any iron studies because they are likely to be a later finding. Iron infusions were not necessarily administered with the objective of treating IDA but rather to avert the possible need for transfusion. Because there is no clinical benefit to transfuse with a hemoglobin level above 10 g/dL, the risk of IV iron infusions seemed to outweigh the benefit, regardless of the iron preparation used. Moderately severe anemia with a hemoglobin level <10 g/dL carries the potential risk for needing a transfusion but still allows some room for IV iron therapy to take effect.
Our report included a heterogeneous group of patients with regard to pathology, age, and comorbidities. We merely aimed to describe the utilization of a new medication that has not specifically been approved for use in pediatrics, with an eye on describing the administration protocol and any adverse drug reactions encountered.
Given the retrospective nature of the review, there was no investigational protocol for patient stratification but rather describing a clinical practice that evolved over a few years. Patients were treated based on more than 1 marker but almost always when they had a hemoglobin level <10 g/dL. Very often mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), reticulocyte count, and Reticulocyte hemoglobin (retic-HB) were also considered to assess bone marrow activity and reflect on iron status. A couple of patients were treated with a hemoglobin level of >10 g/ dL but with rapidly declining levels, low ferritin, and ongoing gastrointestinal blood losses. A ferritin level of <50 ngm/ml was used as a sign of declining iron stores in a patient with low hemoglobin rather than a sole definition of IDA. However, retrospectively, we attempted to stratify patients by demographics, primary diagnoses, concomitant therapies for inflammatory bowel disease, concomitant comorbidities, and erythropoietin therapy. Subgroup sizes were often too small to be meaningful, except where we had made a reference of better response to therapy in those without comorbidities and in those with concomitant erythropoietin use. Finally, we have attempted to look at patients who had concomitant CRPs of 50, 100, and 150 ng/mL, but the number of patients was very small in the high-value groups to be able to perform sound statistical testing. Our study merely showed the feasibility of ferumoxytol use in the pediatric population, a dosing suggestion, and adverse effects that could potentially be detected and treated with a slower infusion rate than that originally suggested. 
